On December 2, 2025, SPARC announced that the US District Court for the District of Columbia had granted its motion for summary judgment in a case related to the issuance of PRVs linked to Sezabi’s approval. The court ruled that the US The Food and Drug Administration’s (FDA) decision to stop PRV was “unlawful”, noting that no drug product containing phenobarbital sodium had been “previously approved”, as defined under the relevant statute. The court has given 60 days time for appeal.
Commenting on the decision, SPARC CEO Anil Raghavan said, “We are pleased with the ruling issued today by the US District Court, as it validates SPARC’s longstanding position on this matter.”
Sezabi is a benzyl alcohol- and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was approved by the US FDA for the treatment of neonatal seizures, providing a safe option for newborns requiring this complex therapy.
Technology at SPARC: The 14-day Relative Strength Index (RSI) for SPARC is currently at 76.8. RSI values above 70 generally indicate that the stock is overbought, indicating that SPARC may experience a short-term price pullback or correction.
Moving Averages: On the positive side, SPARC is trading above all its 8 key Simple Moving Averages (SMAs), indicating a strong bullish trend in its short- to medium-term price movements.
Also Read: Meesho IPO opens for bidding Check GMP, Price Band, Review, Subscription and other key details
Financial Performance: Despite these technical positives, SPARC has been making losses for the last 8 consecutive quarters.
(disclaimer: Recommendations, suggestions, opinions and views given by experts are their own. (These do not represent the views of The Economic Times)
As a trusted and reliable news source
Add now!
(You can now subscribe to our ETMarkets WhatsApp channel)